Saturday , November 18 2017
Home / Specialties / Nephrology / Dr. Matthew Weir Part 2, Cardiovascular and Kidney Disease Prevention

Dr. Matthew Weir Part 2, Cardiovascular and Kidney Disease Prevention

At the the AACE 2017 convention in Austin, Texas, Dr. Matthew Weir and Diabetes in Control Publisher Steve Freed discuss the impact of SGLT2 drugs in helpful as well as possibly harmful ways. They also look at the need for safety studies for kidney disease.

Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine at the University of Maryland. Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, cardiovascular disease in patients with chronic kidney disease, and mineralocorticoid receptor antagonism to treat atherosclerosis. 

Return to main page.